TXNIP and lung cancer: And results demonstrated that low levels of TXNIP was closely linked to poor OS, relapse-free survival (RFS), post-progression survival (PPS), and distant metastasis-free survival (DMFS) prognosis for breast cancer (Fig. 2C–F, all P < 0.001); poor OS (P = 0.000), RFS (P = 0.017), progression-free survival (PFS, P = 0.027), and disease specific survival (DSS, P = 0.001) prognosis for liver cancer (Fig. 2G–J); and poor OS (P = 2.7e−10), PPS (P = 0.000), and first progression (FP, P = 0.001) prognosis for lung cancer (Fig. 2K–M).